Drug Trial Radar · NCT07654829
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Nov 29, 2027
Study completion Dec 6, 2027
Sponsor
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
Conditions
- Hereditary Angioedema
Interventions
KVD900 600 mgDrug
KVD900 Tablet 600 mg (2 x 300 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number and proportion of STPs that did not result in an HAE attack within 24 hours after the start of the procedure will be summarized.Time frame: 24 hours following the start of the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
KalVista Investigative Site
Colorado Springs, Colorado · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.